FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2762315257> ?p ?o ?g. }

• W2762315257 endingPage "993" @default.
• W2762315257 startingPage "986" @default.
• W2762315257 abstract "Background and Aim Upper GI endoscopy (UGE) is essential for the diagnosis of gastrointestinal diseases. Mucus and bubbles may decrease mucosal visibility. The use of mucolytics could improve visualization. Our aim was to determine whether premedication with simethicone or simethicone plus N-acetylcysteine is effective in improving visibility during UGE. Methods This was a randomized, double-blinded, placebo-controlled trial with 2 control groups: no intervention and water 100 mL (W); and 3 intervention groups: simethicone 200 mg (S); S + N-acetylcysteine (NAC) 500 mg (S+NAC500); and S + NAC 1000 mg (S+NAC1000). The solution was ingested 20 minutes before UGE. Gastric visibility was evaluated in 4 segments with a previously described scale. A score of less than 7 points was defined as adequate visibility (AV). Water volume was used to improve visibility, and adverse reactions were evaluated as a secondary outcome. Multiple group comparison was performed using non-parametric one-way analysis of variance (ANOVA). Results Two hundred thirty patients were included in the study, 68% female, mean age 49 years. The most common indication for UGE was epigastric pain/dyspepsia (33%). AV was more frequent in the S+NAC500 and S+NAC1000 groups (65% and 67%) compared with no intervention (44%, P = .044) and water (41%, P = .022). The gastric total visibility scale (TVS) was significantly better in the S+NAC500 and S+NAC1000 groups compared with water (P = .03 and P = .008). Simethicone was not different from no intervention and water. S+NAC1000 required less water volume to improve visibility. No adverse reactions from the study drugs were observed. Conclusions Premedication with S+NAC500 and S+NAC1000 improves visibility during UGE. The use of simethicone did not show improvements in gastric visibility. TVS was worse in patients using water alone. (Clinical trial registration number: NCT 01653171.) Upper GI endoscopy (UGE) is essential for the diagnosis of gastrointestinal diseases. Mucus and bubbles may decrease mucosal visibility. The use of mucolytics could improve visualization. Our aim was to determine whether premedication with simethicone or simethicone plus N-acetylcysteine is effective in improving visibility during UGE. This was a randomized, double-blinded, placebo-controlled trial with 2 control groups: no intervention and water 100 mL (W); and 3 intervention groups: simethicone 200 mg (S); S + N-acetylcysteine (NAC) 500 mg (S+NAC500); and S + NAC 1000 mg (S+NAC1000). The solution was ingested 20 minutes before UGE. Gastric visibility was evaluated in 4 segments with a previously described scale. A score of less than 7 points was defined as adequate visibility (AV). Water volume was used to improve visibility, and adverse reactions were evaluated as a secondary outcome. Multiple group comparison was performed using non-parametric one-way analysis of variance (ANOVA). Two hundred thirty patients were included in the study, 68% female, mean age 49 years. The most common indication for UGE was epigastric pain/dyspepsia (33%). AV was more frequent in the S+NAC500 and S+NAC1000 groups (65% and 67%) compared with no intervention (44%, P = .044) and water (41%, P = .022). The gastric total visibility scale (TVS) was significantly better in the S+NAC500 and S+NAC1000 groups compared with water (P = .03 and P = .008). Simethicone was not different from no intervention and water. S+NAC1000 required less water volume to improve visibility. No adverse reactions from the study drugs were observed. Premedication with S+NAC500 and S+NAC1000 improves visibility during UGE. The use of simethicone did not show improvements in gastric visibility. TVS was worse in patients using water alone. (Clinical trial registration number: NCT 01653171.)" @default.
• W2762315257 created "2017-10-20" @default.
• W2762315257 creator A5011675139 @default.
• W2762315257 creator A5022595025 @default.
• W2762315257 creator A5022984477 @default.
• W2762315257 creator A5029266543 @default.
• W2762315257 creator A5045932114 @default.
• W2762315257 creator A5047713195 @default.
• W2762315257 creator A5050275318 @default.
• W2762315257 creator A5053863751 @default.
• W2762315257 creator A5056477467 @default.
• W2762315257 creator A5066965536 @default.
• W2762315257 creator A5072033545 @default.
• W2762315257 creator A5074737071 @default.
• W2762315257 creator A5074971118 @default.
• W2762315257 creator A5082421027 @default.
• W2762315257 date "2018-04-01" @default.
• W2762315257 modified "2023-10-17" @default.
• W2762315257 title "Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy: a double-blind, randomized controlled trial" @default.
• W2762315257 cites W1799274322 @default.
• W2762315257 cites W1967109306 @default.
• W2762315257 cites W1971157498 @default.
• W2762315257 cites W1973248188 @default.
• W2762315257 cites W1987307260 @default.
• W2762315257 cites W2015795623 @default.
• W2762315257 cites W2028314071 @default.
• W2762315257 cites W2044517432 @default.
• W2762315257 cites W2045358431 @default.
• W2762315257 cites W2052464337 @default.
• W2762315257 cites W2057440604 @default.
• W2762315257 cites W2073587414 @default.
• W2762315257 cites W2080295615 @default.
• W2762315257 cites W2090355778 @default.
• W2762315257 cites W2108696783 @default.
• W2762315257 cites W2154085198 @default.
• W2762315257 cites W2157370011 @default.
• W2762315257 cites W2158866939 @default.
• W2762315257 cites W2160533697 @default.
• W2762315257 cites W2172422824 @default.
• W2762315257 cites W2289706326 @default.
• W2762315257 cites W2291669041 @default.
• W2762315257 cites W2328727400 @default.
• W2762315257 cites W2625146422 @default.
• W2762315257 cites W4252127747 @default.
• W2762315257 doi "https://doi.org/10.1016/j.gie.2017.10.005" @default.
• W2762315257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29037773" @default.
• W2762315257 hasPublicationYear "2018" @default.
• W2762315257 type Work @default.
• W2762315257 sameAs 2762315257 @default.
• W2762315257 citedByCount "39" @default.
• W2762315257 countsByYear W27623152572018 @default.
• W2762315257 countsByYear W27623152572019 @default.
• W2762315257 countsByYear W27623152572020 @default.
• W2762315257 countsByYear W27623152572021 @default.
• W2762315257 countsByYear W27623152572022 @default.
• W2762315257 countsByYear W27623152572023 @default.
• W2762315257 crossrefType "journal-article" @default.
• W2762315257 hasAuthorship W2762315257A5011675139 @default.
• W2762315257 hasAuthorship W2762315257A5022595025 @default.
• W2762315257 hasAuthorship W2762315257A5022984477 @default.
• W2762315257 hasAuthorship W2762315257A5029266543 @default.
• W2762315257 hasAuthorship W2762315257A5045932114 @default.
• W2762315257 hasAuthorship W2762315257A5047713195 @default.
• W2762315257 hasAuthorship W2762315257A5050275318 @default.
• W2762315257 hasAuthorship W2762315257A5053863751 @default.
• W2762315257 hasAuthorship W2762315257A5056477467 @default.
• W2762315257 hasAuthorship W2762315257A5066965536 @default.
• W2762315257 hasAuthorship W2762315257A5072033545 @default.
• W2762315257 hasAuthorship W2762315257A5074737071 @default.
• W2762315257 hasAuthorship W2762315257A5074971118 @default.
• W2762315257 hasAuthorship W2762315257A5082421027 @default.
• W2762315257 hasConcept C120665830 @default.
• W2762315257 hasConcept C121332964 @default.
• W2762315257 hasConcept C123403432 @default.
• W2762315257 hasConcept C126322002 @default.
• W2762315257 hasConcept C141071460 @default.
• W2762315257 hasConcept C142724271 @default.
• W2762315257 hasConcept C168563851 @default.
• W2762315257 hasConcept C185592680 @default.
• W2762315257 hasConcept C197934379 @default.
• W2762315257 hasConcept C204787440 @default.
• W2762315257 hasConcept C27081682 @default.
• W2762315257 hasConcept C2777847592 @default.
• W2762315257 hasConcept C2778004101 @default.
• W2762315257 hasConcept C2778451229 @default.
• W2762315257 hasConcept C55493867 @default.
• W2762315257 hasConcept C71924100 @default.
• W2762315257 hasConcept C90924648 @default.
• W2762315257 hasConceptScore W2762315257C120665830 @default.
• W2762315257 hasConceptScore W2762315257C121332964 @default.
• W2762315257 hasConceptScore W2762315257C123403432 @default.
• W2762315257 hasConceptScore W2762315257C126322002 @default.
• W2762315257 hasConceptScore W2762315257C141071460 @default.
• W2762315257 hasConceptScore W2762315257C142724271 @default.
• W2762315257 hasConceptScore W2762315257C168563851 @default.
• W2762315257 hasConceptScore W2762315257C185592680 @default.
• W2762315257 hasConceptScore W2762315257C197934379 @default.
• W2762315257 hasConceptScore W2762315257C204787440 @default.

• next